Is Ikena Oncology Stock a Good Investment?
Ikena Oncology Investment Advice | IKNA |
- Examine Ikena Oncology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Ikena Oncology's leadership team and their track record. Good management can help Ikena Oncology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Ikena Oncology's business and its evolving consumer preferences.
- Compare Ikena Oncology's performance and market position to its competitors. Analyze how Ikena Oncology is positioned in terms of product offerings, innovation, and market share.
- Check if Ikena Oncology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Ikena Oncology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ikena Oncology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ikena Oncology is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Ikena Oncology Stock
Researching Ikena Oncology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 88.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.5. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ikena Oncology recorded a loss per share of 1.02. The entity had not issued any dividends in recent years.
To determine if Ikena Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ikena Oncology's research are outlined below:
| Ikena Oncology generated a negative expected return over the last 90 days | |
| Ikena Oncology may become a speculative penny stock | |
| Ikena Oncology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (49.23 M) with loss before overhead, payroll, taxes, and interest of (30.88 M). | |
| Ikena Oncology currently holds about 192.81 M in cash with (46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 88.0% of the company shares are owned by institutional investors |
Ikena Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ikena Oncology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ikena Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Ikena Oncology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 63.22 M.Basic technical analysis of Ikena Stock
As of the 22nd of March, Ikena Oncology retains the Market Risk Adjusted Performance of (3.16), standard deviation of 2.5, and Risk Adjusted Performance of (0.1). Ikena Oncology technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Ikena Oncology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ikena Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ikena Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ikena Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ikena Oncology's Outstanding Corporate Bonds
Ikena Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ikena Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ikena bonds can be classified according to their maturity, which is the date when Ikena Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| iHeartCommunications 6375 percent Corp BondUS45174HBC07 | View | |
| iHeartCommunications 8375 percent Corp BondUS45174HBD89 | View | |
| iHeartCommunications 475 percent Corp BondUS45174HBG11 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Ikena Oncology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Ikena Oncology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (3.16) | |||
| Mean Deviation | 1.9 | |||
| Coefficient Of Variation | (836.31) | |||
| Standard Deviation | 2.5 | |||
| Variance | 6.24 | |||
| Information Ratio | (0.1) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.12) | |||
| Treynor Ratio | (3.17) | |||
| Maximum Drawdown | 8.93 | |||
| Value At Risk | (3.38) | |||
| Potential Upside | 4.58 | |||
| Skewness | 0.0406 | |||
| Kurtosis | 1.24 |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (3.16) | |||
| Mean Deviation | 1.9 | |||
| Coefficient Of Variation | (836.31) | |||
| Standard Deviation | 2.5 | |||
| Variance | 6.24 | |||
| Information Ratio | (0.1) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | (0.12) | |||
| Treynor Ratio | (3.17) | |||
| Maximum Drawdown | 8.93 | |||
| Value At Risk | (3.38) | |||
| Potential Upside | 4.58 | |||
| Skewness | 0.0406 | |||
| Kurtosis | 1.24 |
Consider Ikena Oncology's intraday indicators
Ikena Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ikena Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ikena Oncology time-series forecasting models is one of many Ikena Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ikena Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Ikena Stock media impact
Far too much social signal, news, headlines, and media speculation about Ikena Oncology that are available to investors today. That information is available publicly through Ikena media outlets and privately through word of mouth or via Ikena internal channels. However, regardless of the origin, that massive amount of Ikena data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ikena Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ikena Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ikena Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ikena Oncology alpha.
Ikena Oncology Corporate Management
| Navin MS | VP Quality | Profile | |
| Sabine Ruppel | VP Discovery | Profile | |
| Jennifer Schroeder | Sr Operations | Profile | |
| Rebecca Cohen | Corporate Relations | Profile | |
| Valdas Jurkauskas | Senior Operations | Profile | |
| MBA MD | Chief Officer | Profile | |
| David MS | Senior Operations | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Ikena Oncology's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.